

**DFNA5 Antibody (N-term) Blocking Peptide**  
**Synthetic peptide**  
**Catalog # BP6842a****Specification**

---

**DFNA5 Antibody (N-term) Blocking Peptide - Product Information**Primary Accession [O60443](#)**DFNA5 Antibody (N-term) Blocking Peptide - Additional Information****Gene ID** 1687**Other Names**

Non-syndromic hearing impairment protein 5, Inversely correlated with estrogen receptor expression 1, ICERE-1, DFNA5, ICERE1

**Target/Specificity**

The synthetic peptide sequence used to generate the antibody [AP6842a](/products/AP6842a) was selected from the N-term region of human DFNA5. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

**Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

**Storage**

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

**Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

**DFNA5 Antibody (N-term) Blocking Peptide - Protein Information****Name** GSDME {ECO:0000303|PubMed:28459430, ECO:0000312|HGNC:HGNC:2810}**Function**

[Gasdermin-E]: Precursor of a pore-forming protein that converts non-inflammatory apoptosis to pyroptosis (PubMed: [27281216](http://www.uniprot.org/citations/27281216), PubMed: [28459430](http://www.uniprot.org/citations/28459430), PubMed: [33852854](http://www.uniprot.org/citations/33852854), PubMed: [35594856](http://www.uniprot.org/citations/35594856)). This form constitutes the precursor of the pore-forming protein: upon cleavage, the released N-terminal moiety (Gasdermin-E, N-terminal) binds to membranes and forms pores, triggering pyroptosis (PubMed: [28459430](http://www.uniprot.org/citations/28459430)).

**Cellular Location**

[Gasdermin-E, N-terminal]: Cell membrane; Multi-pass membrane protein  
{ECO:0000250|UniProtKB:Q5Y4Y6}

**Tissue Location**

Expressed in cochlea (PubMed:9771715). Low level of expression in heart, brain, placenta, lung, liver, skeletal muscle, kidney and pancreas, with highest expression in placenta (PubMed:9771715).

**DFNA5 Antibody (N-term) Blocking Peptide - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

**DFNA5 Antibody (N-term) Blocking Peptide - Images****DFNA5 Antibody (N-term) Blocking Peptide - Background**

Hearing impairment is a heterogeneous condition with over 40 loci described. DFNA5 is expressed in fetal cochlea, however, its function is not known.

**DFNA5 Antibody (N-term) Blocking Peptide - References**

Cheng,J., et.al., Clin. Genet. 72 (5), 471-477 (2007)